Insights into the Overcoming EGFR Del19/T790M/C797S Mutation: A Perspective on the 2‐Aryl‐4‐aminothienopyrimidine Backbone
ChemMedChem · 2024
DOI: 10.1002/cmdc.202300634 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Xuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road…. Hauptthemen laut MEDLINE: Antineoplastic Agents, ErbB Receptors, Mutation, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi, China, Education Department of Jiangxi Province, China.
Abstract (Originalsprache)
The epithelial growth factor receptor (EGFR) signaling pathway has been proposed to benefit non‐small cell lung cancer (NSCLC) treatment. In this manuscript, we investigated the modification of 2‐aryl‐4‐aminoquinazoline, the classical backbone of the fourth‐generation EGFR inhibitors, in addition to obtaining a series of novel 2‐aryl‐4‐aminothienopyrimidine derivatives ( A1~A45 ), we also gained further understanding of the modification of this framework. Derivatives were tested for cytotoxicity against cancer cell lines (cervical cancer cell line Hela, lung cancer cell lines A549, H1975, and PC‐9, Ba/F3‐EGFR Del19/T790M/C797S cells, and human normal hepatocytes LO 2 ) as well as for the derivative‘s inhibitory activity against EGFR WT , EGFR L858R/T790M , and EGFR Del19/T790M/C797S kinase inhibitory activities. The results showed that most of the target compounds showed moderate to excellent activity against one or more cancer cell lines. Among them, the antitumor activity (IC 50 ) of the most promising A9 against A549 and H1975 cell lines was 0.77±0.08 μM, 6.90±0.83 μM, respectively. At concentration of 10 μM, A9 can be employed as the fourth‐generation of EGFR inhibitors with the ability to overcome the C797S drug resistance since it can suppress EGFR Del19/T790M/C797S cells and kinase by 98.90 % and 85.88 %, respectively. Moreover, the tumor‐bearing nude mice experiment further shows that A9 can significantly inhibit the growth of tumor in vivo , with the tumor inhibition rate (TIR) of 55.92 %, which was equivalent to the positive group. After that, from the result of HE staining experiment and blood biochemical analysis experiment, A9 show low toxicity and good safety, which is worthy of further research and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi 330013, China.
ORCID-Profile: Wufu Zhu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi, China
- Education Department of Jiangxi Province, China
- Jiangxi Science & Technology Normal University
- Nanchang Key Laboratory of Molecular Targeted Anticancer Drug Design and Evaluation
Zitieren
APA
Zhang, X., He, J., Xu, S., Fu, L., Zheng, P., Xu, S., Pan, Q., & Zhu, W. (2024). Insights into the Overcoming EGFR Del19/T790M/C797S Mutation: A Perspective on the 2‐Aryl‐4‐aminothienopyrimidine Backbone. ChemMedChem. https://doi.org/10.1002/cmdc.202300634
Vancouver
Zhang X, He J, Xu S, Fu L, Zheng P, Xu S, et al. Insights into the Overcoming EGFR Del19/T790M/C797S Mutation: A Perspective on the 2‐Aryl‐4‐aminothienopyrimidine Backbone. ChemMedChem. 2024. doi:10.1002/cmdc.202300634
BibTeX
@article{Zhang2024,
author = {Zhang, Xuan and He, Jie and Xu, Shidi and Fu, Li and Zheng, Pengwu and Xu, Shan and Pan, Qingshan and Zhu, Wufu},
title = {Insights into the Overcoming EGFR Del19/T790M/C797S Mutation: A Perspective on the 2‐Aryl‐4‐aminothienopyrimidine Backbone},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202300634}
}
EUVIMED